Spi-1 proto-oncogene regulates mRNA hypertranscription and malignant progression in head and neck cancer

This #STTT study identified that SPI1 drives mRNA hypertranscription in head and neck cancer squamous cell carcinoma, promoting oncogenic signaling, tumor progression, and poor clinical outcomes. #HNSCC
#OpenAccess: doi.org/10.1038/s413...

Kaplan-Meier curves for progression-free survival (PFS). Graph A displays PFS by BMI category(Normal, Underweight, Overweight, Obesity). Graph B shows PFS by BMI change group(Decreased <2%, Decreased ≥2%). Graph C represents PFS by PNI category(Normal PNI, Low PNI).

Pretreatment BMI loss and low PNI predicted shorter progression-free survival in immunotherapy-treated #HNSCC, while baseline BMI category was not associated with outcome. ja.ma/4sMn6vf

#TenascinC orchestrates #radiotherapy -induced head and neck tumor regression #HNSCC by T. Loustau, G. Orend & colleagues @unistra.fr @inserm.fr

🗞️ doi.org/10.1038/s44321-026-00406-8

This #STTT study reveals that the Spi-1 #ProtoOncogene regulates mRNA hypertranscription to drive malignant progression in #HNSCC, offering a novel #TherapeuticTarget for hypertranscriptional HNSCC subtypes.

#OpenAccess: doi.org/10.1038/s413...

The combo of tislelizumab and chemotherapy produced sustained and clinically meaningful survival benefits with manageable toxicity among patients with recurrent or metastatic #nasopharyngealCancer. From @jamaoncology.com

Read more here: ➡️ https://bit.ly/4rTgs5h

#HeadandNeckCancer #HNSCC #MedOnc

Keytruda cleared for NHS use in early head and neck cancer MSD's Keytruda is poised to end a 20-year drought in new advances in NHS treatment for early-stage head and neck cancer

#Keytruda #pembrolizumab #immunotherapy #headandneckcancer #PharmaNews #MSD #NICE #reimbursement #NICEfinaldraftguidance #NHSEngland #headandnecksquamouscellcarcinoma #HNSCC #LAHNSCC #PDL1biomarker #PD1inhibitor #KEYNOTE689trial #perioperativeimmunotherapy #PDL1positiveHNSCC
zurl.co/y2cQh

Waterfall plot showing change in longest diameter of primary tumor. Y-axis labeled 'Change in longest diameter of primary tumor, %' ranges from -100 to 100. X-axis labeled 'Patients'. Plot shows progressive, stable, partial, and complete responses.

Intratumoral NBTXR3 followed by #Radiotherapy showed feasibility and promising response rates in cisplatin- or cetuximab-ineligible patients with locally advanced #HNSCC. ja.ma/4uFjVXr

#FGF9 #HNSCC #HeadandNeckSquamousCellCarcinima

High FGF9 HR=2.5⬇️HNSCC survival

7-gene NOTCH module score➡️
Survival
Immunosuppressive TME
Anti-PD-1 immunotherapy response (low NOTCH score 92%; high 8%)
Chemo sensitivity

#JStomatolOralMaxillofacSurg 2025
www.sciencedirect.com/science/arti...

Data from an exploratory expansion cohort of a phase 1b trial showed less-frequent dosing of ficerafusp alfa in combination with pembrolizumab produced deep and durable responses in patients with recurrent/metastatic #HNSCC #oncology

Read more: www.onclive.com/view/less-fr...

JAMA Otolaryngology-Head & Neck Surgery journal cover. Title: Individualized Prognostic Counseling for Decision-Making in Head and Neck Cancer. Authors: Maarten C. Dorr, Arta Hoesseini, Aniel Sewnaik. Published Online: January 2, 2026.

Individualized prognostic counseling using an online model was linked to reduced decisional conflict and regret and more active decision-making in #HNSCC patients.

ja.ma/4be5a6v

A phase 1 study of berzosertib (M6620, VX‐970) in combination with cisplatin and radiation in patients with locally advanced head and neck squamous cell carcinoma (ETCTN 9950) In a phase 1 trial, selective ATR inhibitor berzosertib with definitive radiation and cisplatin in locally advanced head and neck squamous cell cancers was well tolerated but did not improve complete....

A Phase 1 study by Dr. Aarti Bhatia combined berzosertib with cisplatin + RT in LA #HNSCC. The regimen was feasible + safe, but did not improve response rates compared w/historical chemoradiation—highlighting the need for better radiosensitizers.
acsjournals.onlinelibrary.wiley.com/doi/10.1002/...

Figure 2: Genomic Landscape and Longitudinal Minimal Residual Disease Dynamics. Chart A: Oncoplot showing gene variants like TTN, TP53, FAT1 and variant types. Chart B: Gene variants by stage, with bar graphs showing percentage of patients carrying variants.

In patients with locally advanced #HNSCC, ctDNA-based minimal residual disease positivity after treatment completion was associated with higher recurrence and worse survival, supporting its use as a prognostic biomarker. ja.ma/46YDqQL

The graphic shows four plots: An Alluvial plot about trial phase and reasons for failure, a graph of reasons for failure by treatment type, a graph of reason for failure by funder type, and a scatter plot showing principal components.

Strategic sponsor decisions and poor accrual are the leading reasons for early termination of #HNSCC clinical trials, especially in industry-funded and phase 1 studies. ja.ma/4urXGEf

JAMA Otolaryngology-Head & Neck Surgery journal excerpt. Headline: Neoadjuvant Immunotherapy and Chemoimmunotherapy Regimens in Head and Neck Cancer. Authors: Hannah Q. Baratz, et al. Published online: March 12, 2026. doi: text@1

Neoadjuvant chemoimmunotherapy for resectable locoregionally advanced head and neck squamous cell carcinoma (#HNSCC) was associated with higher rates of major and complete pathologic response compared with immunotherapy alone.

ja.ma/4smWxw9

#MHNCS26 phase II trial of the trop-2 / Topo 1 ADC, Sacituzumab Govitecan in recurrent post PD1 metastatic #HNSCC presented as a TIP #MedIQMHNCS26

#MHNCS26 encouraging results of NBTXR3 with SBRT in recurrent post PD1 failure R/M #HNSCC with ORR exceeding 60% in this early data #MedIQMHNCS26

#MHNCS 26 FORTIFI HN01 A pivotal phase III trial examining Ficerafusp Alfa + Pembro vs Pembro in HPV unrelated #HNSCC, TIP presentation #MedIQMHNCS26

#MHNCS26 AHEAD MERIT pivotal phase II / III trial of HPV 16 E6,E7 mRNA immunotherapy : BNT 113 + Pembro vs Pembro in RM PDL1 + HPV 16 #HNSCC, TIP #MedIQMHNCS26

#MHNCS26 updates from KN689 as to surgical data; EFS correlates with mPR; surgical rate is similar in both arms, #MedIQMHNCS26 #HNSCC

#MHNCS26 predictive and prognostic IO markers to be analyzed for R/M #HNSCC in the Phoenix tissue procurement study, so far 52 patients enrolled; a TIP poster session #MedIQMHNCS26

#MHNCS26 ongoing Evolve trial is a global study of Volrustamab vs observation post definitive Chemo RT in LA #HNSCC updated in a TIP poster session #MedIQMHNCS26

#MHNCS26 preoperative SC Amivantamab shows tolerability and encouraging responses with ORR of 46% in this cohort of pre and post Ami + Pembro resectable HPV - #HNSCC #MedIQMHNCS26

#MHNCS26 the only STAT3 targeted ASO shows no increase in response compared to single agent Pembro in 1st line randomized PEMDA Denvatirsen Pembro vs Pembro phase II study #MedIQMHNCS26 #HNSCC

#MHNCS26 encouraging responses with Ficerafusp Alfa 2000 mg Q 2 weeks and Pembro 400 Q 6 in 1st line RM HPV - HNSCC , ORR 48% CR 26% #MedIQMHNCS26 #HNSCC

Encouraging results with ORR 56% CR 10% shrinkage of tumor in 82% in Origami 4 Amivantamab + Pembro cohort #MHNCS26
#MedIQMHNCS26 #HNSCC

Forest plots show associations between treatment response and disease-free survival. Plot A: Partial pathologic response. Plot B: Major pathologic response. Studies include text@11, text@6, text@13, text@19, text@18, text@12, text@22, text@21, text@23.

Among adults with mucosal #HNSCC receiving neoadjuvant immune checkpoint inhibition, pooled analysis demonstrated that partial and major pathologic responses correlated with improved disease-free survival, but not overall survival.

bit.ly/4kiD8JH

AVEO Oncology Completes First Analysis of FIERCE-HN Study for Head and Neck Cancer Treatment AVEO Oncology announces the successful completion of the first interim analysis for the global FIERCE-HN study, focusing on a promising combination therapy for patients with advanced head and neck cancer.

AVEO Oncology Completes First Analysis of FIERCE-HN Study for Head and Neck Cancer Treatment #United_States #Boston #AVEO_Oncology #HNSCC #ficlatuzumab

🦙 Our new #review article is out now.💡
In "Ancient and Emerging Nanostructures for Innovations to Fight #HeadandNeckCancer" we highlight how diverse technologies are shaping the future for #HNSCC thearpy, also including our research focus about #Nanobodies🦙
Read more 👉 www.mdpi.com/2073-4409/15...

CDK7 targeting suppresses #HNSCC progression by downregulating genes involved in cell cycle progression & #DNARepair, highlighting CDK7 inhibition as a potent therapeutic strategy to overcome treatment resistance. @universidadoviedo.bsky.social

#OpenAccess: doi.org/10.1038/s413...

PD-1 Inhibition Plus Chemotherapy Offers Survival Benefits in Frontline HNSCC | OncLive Real-world data showed that adding PD-1 inhibitors to induction chemotherapy extended OS and PFS vs chemotherapy alone in frontline HNSCC.

PD-1 Inhibition Plus Chemotherapy Offers Survival Benefits in Frontline HNSCC #oncology #HNSCC
www.onclive.com/view/pd-1-in...